

RESEARCH

Open Access



# COVID-19 hospitalizations in five California hospitals: a retrospective cohort study

Miriam Nuño<sup>1,2\*</sup>, Yury García<sup>1,4</sup>, Ganesh Rajasekar<sup>2</sup>, Diego Pinheiro<sup>3</sup> and Alec J. Schmidt<sup>1</sup>

## Abstract

**Background:** The novel coronavirus pandemic has had a differential impact on communities of color across the US. The University of California hospital system serves a large population of people who are often underrepresented elsewhere. Data from hospital stays can provide much-needed localized information on risk factors for severe cases and/or death.

**Methods:** Patient-level retrospective case series of laboratory-confirmed COVID-19 hospital admissions at five UC hospitals (N = 4730). Odds ratios of ICU admission, death, and a composite of both outcomes were calculated with univariate and multivariate logistic regression based on patient characteristics, including sex, race/ethnicity, and select comorbidities. Associations between comorbidities were quantified and visualized with a correlation network.

**Results:** Overall mortality rate was 7.0% (329/4,730). ICU mortality rate was 18.8% (225/1,194). The rate of the composite outcome (ICU admission and/or death) was 27.4% (1298/4730). Comorbidity-controlled odds of a composite outcome were increased for age 75–84 (OR 1.47, 95% CI 1.11–1.93) and 85–99 (OR 1.39, 95% CI 1.04–1.87) compared to 18–34 year-olds, males (OR 1.39, 95% CI 1.21–1.59) vs. females, and patients identifying as Hispanic/Latino (OR 1.35, 95% CI 1.14–1.61) or Asian (OR 1.43, 95% CI 1.23–1.82) compared to White. Patients with 5 or more comorbidities were exceedingly likely to experience a composite outcome (OR 2.74, 95% CI 2.32–3.25).

**Conclusions:** Males, older patients, those with multiple pre-existing comorbidities, and those identifying as Hispanic/Latino or Asian experienced an increased risk of ICU admission and/or death. These results are consistent with reported risks among the Hispanic/Latino population elsewhere in the United States, and confirm multiple concerns about heightened risk among the Asian population in California.

**Keywords:** Severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, Hospitalization, Comorbidities, Intensive care unit, In-hospital mortality, Composite outcome

## Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19) has been a devastating pandemic, with over 91 million confirmed cases and nearly 2 million deaths worldwide [1]. In the United States, the state of California (hereafter referred to as CA) leads the charts for

the worse surge across the nation, with a total of 70,561 confirmed cases per million residents, 1176 confirmed deaths per million residents, and potentially 1173 ICU beds available for a population of nearly 40 million (January 12, 2021).

Advanced age, chronic underlying conditions (including hypertension, diabetes, chronic kidney disease, among others), and being male are associated with an increased risk of hospitalization and death from COVID-19 [2–14]. There is additional, mounting evidence that some racial and ethnic minority groups are at disproportionate risk [3, 5, 6, 11]. Nation-wide, the Black/African

\*Correspondence: mnuno@ucdavis.edu

<sup>1</sup> Department of Public Health Sciences, University of California, One Shields Avenue, Medical Sciences 1C, Davis, CA 95616, USA

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

American, Hispanic/Latino, Asian, and American Indian/Alaskan Native (AIAN) populations have seen elevated crude rates of infection, hospitalization, and/or mortality compared to the White population [15]. In trends similar to other states, estimates from CA indicate that the Hispanic/Latino population make up 55% of confirmed cases and 47% of deaths and only 39% of the total population the Black/African American population represent 4% of confirmed cases and 7% of deaths and only 6% of the total population; and the Asian population represent 7% of all cases but 12% of all deaths. Multiple informal analyses report that Asians have low rates of confirmed cases but concerningly high case fatality rates [16], but few studies have been large enough to capture associated risk factors in this population.

More diverse, localized information is needed about who is being hospitalized with COVID-19 and their outcomes in the United States, and California in particular, especially since the second surge in the last half of 2020. This study describes the demographic characteristics, baseline comorbidities, and outcomes of patients hospitalized with COVID-19 in five acute care medical centers in the University of California Health System.

## Methods

### Data collection and cohort identification

In this retrospective cohort study, we identified patients who were hospitalized with laboratory-confirmed SARS-CoV-2 infections at any of the five UC Health hospitals between December 13, 2019 and January 6, 2021 by extracting electronic medical records (EMRs) from The COVID Research Data Set (CORDS). The index date corresponds to the first confirmed COVID-19 diagnosis. A hospitalization was included if test confirmation occurred within 21 days or during an inpatient admission. SARS-CoV-2 positive status was determined by PCR or SNOMED code 840539006 (Disease caused by Severe acute respiratory syndrome coronavirus 2) during their earliest hospitalization (Additional file 1: Table S1).

Patient characteristics, including race/ethnicity, sex, comorbidities, and clinical outcomes were collected. Data was queried on January 8, 2021 and tabulated by January 10, 2021. We captured comorbidities using the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)* classification (Additional file 1: Table S2). Self-identified race/ethnicity was categorized into White, Hispanic/Latino, Black/African American, and Asian; Other includes AIAN (n=9, 0.19%), Native Hawaiian or Other Pacific Islander (n=53, 1.12%), Other (n=169, 3.57%), Unknown (n=246, 5.20%), and those that identified with multiple race/ethnicity (n=46, 0.97%).

Comorbidities included cancer, cardiac disease, cerebrovascular disease, coagulopathy, deficiency anemia, depression, diabetes, drug use disorders, HIV/Aids, hypertension, hypothyroidism, liver disease, neurological conditions, obesity, paralysis, pregnancy, psychoses, pulmonary disease, renal failure, collagen vascular disease, smoking status, and solid organ transplantation. Comorbidities documented 2 months prior to COVID-19 confirmation, during hospitalization, or 2 months post discharge were considered. The 2 month post-discharge observation period to capture comorbidities was deemed reasonable given lags in data entry due to billing. A comorbidity score represented the sum of any of these conditions. The lowest score of a 0 (n=1806, 38.2%) was assigned to patients without documented comorbidities. The co-occurrence of comorbidities was illustrated through correlation networks. The UC Davis implementation of the University of California COVID Research Data Set (CORDS) was determined exempt from human subject protection under IRB protocol 1604619-1. Informed Consent was not deemed necessary for de-identified data by Nicholas and Kent Anderson at the UC Davis Clinical and Translational Science Award (CTSC) Biomedical Informatics Program.

### Statistical analysis

Univariate logistic regression was used to calculate the crude odds ratio (OR) of ICU admission and mortality events to discharge from the hospital. Multivariable logistic regression was used to estimate the odd ratio of the composite outcome of ICU admission and/or death during hospitalization to discharge from the hospital. The multivariable model adjusted for age in years at admission, sex, and race/ethnicity. Odds ratios and 95% confidence intervals (95% CI) were reported.

We measured the strength of comorbidity associations with the Pearson’s correlation coefficient ( $\Phi$ ) for binary variables. The correlation coefficient between a pair of comorbidities,  $\Phi_{ij}$ , was calculated according to Equation (1) below.

$$\Phi_{ij} = \frac{C_{ij}N - P_iP_j}{\sqrt{P_iP_j(N - P_i)(N - P_j)}} \tag{1}$$

where  $C_{ij}$  corresponds to the number of patients affected by both comorbidities,  $N$  is the total number of patients in the study, and  $P_i$  is the prevalence of the  $i$ th comorbidity. The distribution of  $\Phi$  values represent all disease pairs where  $C_{ij} > 0$ . The correlation for the dichotomous variable is denoted by  $\Phi$  and a t-test is used to determine the significance of  $\Phi \neq 0$  [17].

We visualized comorbidities with correlation ( $\Phi > 0$ ) larger than expected by chance for the entire cohort, as well as stratified by composite outcome.

We described patterns in cumulative hospitalizations during the study period over time by using change-point analysis to discern specific time points where abrupt changes in the mean occurred. This algorithm detects multiple points of change in time-ordered data through binary segmentation [18–20]. First, we applied a change-point statistical test to the entire time series of hospitalization cases. Then, we split the series into two new ones when a point change was found. We repeated this procedure several times until there were no further significant change points. Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, NC, USA), the *changept* package (binary segmentation algorithm) in R version 4.0.1 (R Core Team 2020), and Python. Data were analyzed from January 8 to January 20, 2021.

## Results

A total of 4,730 hospitalized patients with positive SARS-CoV-2 assays were included (median age 61 years, IQR: 46–73) (Table 1). 56.4% were male; one patient was missing sex data. A total of 339 (7.2%) identified as Black/African American, 2161 (45.7%) as Hispanic/Latino, 489 (10.3%) as Asian, 523 (11.1%) were documented as Other/Unknown, and 1218 (25.8%) identified as White. A moderate fraction of patients did not have documented comorbidities ( $n = 1806$ , 38.2%). The most common comorbidities were hypertension (35.2%), cardiac disease (33.3%), diabetes (24.0%), pulmonary disease (17.8%), obesity (17.3%), and renal failure (15.3%). Coagulopathy (11.8%), smoking (10.2%), depression (9.4%), liver disease (8.8%), and cerebrovascular disease (7.8%) were also reported. Among the possible 22 comorbidities documented for each individual patient, we found that 457 (9.7%) patients had one, 488 (10.2%) had two, 468 (9.9%) had three, 430 (9.1%) had four, 355 (7.5%) had five, and 726 (15.4%) had six or more comorbidities.

### Quantifying the strength of comorbidity relationships

We quantified the network of comorbidities and visualized correlations that were positive and significant by linking chronic conditions in a visual network (Fig. 1). Figure 1A displays correlations across the total cohort, of which hypertension and heart disease showed the strongest correlation; Fig. 1B displays the correlation network among patients that did not experience a composite outcome; and Fig. 1C describes the correlation network of comorbidities for patients that experienced a composite outcome. Figure 1B and C together suggest that hypertension, diabetes, cardiac disease, renal

failure, neurological disease, and depression, among other diseases, tend to be more comorbid in individuals that experienced a composite outcome than in those that did not. The comorbidity network structure in Fig. 1A summarized and reflected well-known associations with COVID-19 hospitalizations, while suggesting that the interactions between comorbidities are expressed differently in those with more severe and deadly cases.

### Quantifying changes in hospitalization, ICU admission and in-hospital mortality

Figure 2 shows the daily cumulative COVID-19-related hospital admissions, ICU admissions, and deaths during hospitalization. Change-point analysis showed that April 18, May 18, June 25, August 14, September 11, October 15, and November 21 corresponded to significant abrupt changes in the number of hospitalizations. Similar analysis for the number of ICU admissions and deaths are included in Additional file 1: Figure S1. Similar abrupt changes in ICU admissions occurred on the same dates as those for hospitalization; death trends changed on April 15, May 26, July 3, August 6, September 13, October 16, and November 22, 2020.

### Univariable analysis: ICU admission

We identified 1194 (25.2%) patients who were admitted to the intensive care unit with confirmed infection with SARS-CoV-2 (Table 1). In unadjusted univariate analyses, patients of age 55–74 and 75–84 years were more likely to be admitted to the ICU than 18–44 year-olds, and ICU admission was more likely in male patients than female. Hispanic/Latino, Black/African American, and Asian patients were no more or less likely to be admitted to the ICU once in the hospital than White patients, though Other races/ethnicities were (OR 1.36, 95% CI 1.08–1.71). Among the common comorbidities, the most likely to be admitted to the ICU were those patients with neurological conditions (OR 2.84, 95% CI 2.40–3.35), coagulopathy (OR 2.66, 95% CI 2.22–3.19), and cerebrovascular disease (OR 2.49, 95% CI 2.00–3.09). Other high-risk chronic conditions included cardiac disease, pulmonary disease, diabetes, hypertension, obesity, liver disease, and renal failure.

### Univariable analysis: in-hospital deaths

A total of 329 (7.0%) died during hospitalization (Table 1). The risk of in-hospital mortality increased significantly with age, particularly among patients of age 85 years and older (OR 10.25, 95% CI 5.49–21.34) compared to 18–34 year-olds. Male patients were more likely to die in-hospital than female (OR 1.38, 95% CI 1.09–1.74). Hispanic/Latino, and Other patients were no more or less likely to die than White; however, Asians showed


**Table 1** Characteristics and comorbidities of 4730 patients with COVID-19 hospitalized in UC Health Hospitals

Characteristic	No. patients n = 4730	ICU admission		In-hospital mortality	
		Cases (%) n = 1194 (25.2)	Crude OR (95% CI)	Cases (%) n = 329 (7.0)	Crude OR (95% CI)
Age in years, n (%)					
18–34	587 (12.4)	124 (21.1)	Reference	10 (1.7)	Reference
35–54	1204 (25.5)	287 (23.8)	1.17 (0.92–1.49)	43 (3.6)	2.14 (1.11–4.53)
55–74	1861 (39.3)	514 (23.8)	1.43 (1.14–1.79)	125 (6.7)	4.15 (2.28–8.50)
75–84	581 (12.3)	160 (27.6)	1.42 (1.09–1.86)	76 (13.1)	8.68 (4.66–18.04)
85+	497 (10.5)	109 (21.9)	1.05 (0.78–1.40)	75 (15.1)	10.25 (5.49–21.34)
Sex, n (%) <sup>9</sup>					
Female	2061 (43.6)	452 (21.9)	Reference	120 (5.8)	Reference
Male	2668 (56.4)	742 (27.8)	1.37 (1.20–1.57)	209 (7.8)	1.38 (1.09–1.74)
Race/ethnicity, n (%)					
White	1218 (25.6)	284 (23.3)	Reference	77 (6.3)	Reference
Black/African American	339 (7.2)	83 (24.5)	1.06 (0.80–1.40)	30 (8.9)	1.44 (0.91–2.21)
Hispanic/Latino	2161 (45.7)	551 (25.5)	1.13 (0.96–1.33)	144 (6.7)	1.06 (0.80–1.41)
Asian	489 (10.3)	123 (25.2)	1.11 (0.86–1.41)	46 (9.4)	1.54 (1.05–2.24)
Other/Unknown	523 (11.1)	153 (29.3)	1.36 (1.08–1.71)	32 (6.1)	0.97 (0.62–1.46)
Comorbidities, n (%)					
No comorbidity	1806 (38.2)	335 (18.6)	0.55 (0.47–0.63)	82 (4.5)	0.52 (0.40–0.66)
Cancer	191 (4.0)	45 (23.6)	0.91 (0.64–1.27)	20 (10.5)	1.60 (0.97–2.52)
Cardiac disease	1573 (33.3)	582 (37.0)	2.44 (2.13–2.80)	188 (12.0)	2.90 (2.32–3.65)
Cerebrovascular disease	367 (7.8)	160 (43.6)	2.49 (2.00–3.09)	63 (17.2)	3.19 (2.35–4.28)
Coagulopathy	560 (11.8)	246 (42.9)	2.66 (2.22–3.19)	91 (16.3)	3.21 (2.46–4.14)
Deficiency anemia	264 (5.6)	80 (30.3)	1.31 (0.99–1.71)	24 (9.1)	1.37 (0.86–2.07)
Depression	444 (9.4)	116 (26.1)	1.05 (0.84–1.31)	31 (7.0)	1.01 (0.67–1.45)
Diabetes	1137 (24.0)	399 (35.1)	1.90 (1.65–2.20)	120 (10.6)	1.91 (1.51–2.41)
Drug use disorder	242 (5.1)	65 (26.9)	1.09 (0.81–1.46)	12 (5.0)	0.69 (0.36–1.19)
HIV/Aids	444 (9.4)	6 (15.4)	0.54 (0.20–1.19)	3 (7.7)	1.12 (0.27–3.11)
Hypertension	1664 (35.2)	527 (31.7)	1.67 (1.46–1.91)	178 (10.7)	2.31 (1.85–2.90)
Hypothyroidism	340 (7.2)	100 (29.4)	1.26 (0.98–1.60)	35 (10.3)	1.60 (1.09–2.82)
Liver disease	416 (8.8)	149 (35.8)	1.75 (1.41–2.16)	50 (12.0)	1.98 (1.42–2.70)
Neurological conditions	709 (15.0)	314 (44.3)	2.84 (2.40–3.35)	130 (18.3)	4.31 (3.40–5.46)
Obesity	816 (17.3)	275 (33.7)	1.66 (1.41–1.95)	56 (6.9)	0.98 (0.72–1.31)
Paralysis	100 (2.1)	50 (50.0)	3.05 (2.05–4.54)	16 (16.0)	2.63 (1.47–4.42)
Pregnancy	171 (3.6)	21 (12.3)	0.40 (0.25–0.63)	3 (1.8)	0.23 (0.06–0.62)
Psychoses	108 (2.3)	20 (18.5)	0.67 (0.40–1.07)	3 (2.8)	0.38 (0.09–1.01)
Pulmonary disease	844 (17.8)	330 (39.1)	2.25 (1.92–2.63)	122 (14.5)	3.00 (2.36–3.80)
Renal failure	723 (15.3)	255 (35.3)	1.78 (1.50–2.11)	96 (13.3)	2.48 (1.92–3.18)
Collagen vascular disease*	150 (3.2)	45 (30.0)	1.28 (0.89–1.81)	12 (8.0)	1.17 (0.61–2.05)
Smoker	480 (10.2)	147 (30.6)	1.35 (1.10–1.66)	53 (11.0)	1.79 (1.30–2.42)
Solid organ transplantation	221 (4.7)	72 (32.6)	1.46 (1.09–1.94)	15 (6.8)	0.97 (0.55–1.61)

<sup>9</sup> Sex missing in one patient, \*includes rheumatic arthritis

an increased likelihood of in-hospital mortality (OR 1.54, 95% CI 1.05–2.24) and Black/African Americans were trending in the same direction (OR 1.44, 95% CI 0.91–2.21), albeit with a smaller sample (n = 46 vs. 31, respectively). The presence of 12 out of the 22 comorbidities investigated were significantly associated with increased

odds of in-hospital mortality: neurological conditions (OR 4.31, 95% CI 3.40–5.46), coagulopathy (OR 3.21, 95% CI 2.46–4.14), and cerebrovascular disease (OR 3.19, 95% CI 2.35–4.28), had the most pronounced association with in-hospital mortality. Diabetes, hypertension, liver disease, pulmonary disease, renal failure, and a current



smoking history also increased the odds of in-hospital mortality.


**Multivariable analysis: composite outcome**

Overall, 27.4% (1298/4730) of patients requiring a hospitalization for COVID-19 were admitted in the ICU and/or died during their hospitalization, defined here as a “composite outcome.” The rate of patients with a composite outcome differed across the five UC Health Hospitals (UCD: 33.9%, 287/846; UCI: 18.2%, 285/1564; UCLA: 33.1%, 424/1283; UCSD: 22.9%, 108/471; UCSF: 34.2%, 194/566,  $p < 0.001$ ). Composite outcome rates also vary by month of hospital admission for 2020, with an outlier in March of 2020 at UCSF, due to a single hospitalization requiring ICU admission (Fig. 3). In analysis adjusted for age and the number of relevant comorbidities, we found


that older patients (85+ vs. 18–34, OR 1.39, 95% CI 1.04–1.87), male (OR 1.41, 95% CI 1.23–1.61), Hispanic/Latino (OR 1.35, 95% CI 1.14–1.61), and Asian (OR 1.43, 95% CI 1.13–1.82) were more likely to be admitted to the ICU and/or die during hospitalization (Fig. 4). Patients with higher number of comorbidities were also more likely to experience a composite outcome ( $\geq 5$  vs. none, OR 1.74, 95% CI 2.32–3.25).

**Discussion**

In this study of 4730 patients with COVID-19 requiring hospitalization at five hospitals in California, 25.2% were admitted to the ICU, and 7.0% died. Patients were older (20% greater than 75 years), largely Hispanic/Latino (45.7%), with moderate representation of White (25.8%), Asian (10.3%), and Black/African American (7.2%). The




**Fig. 2** Cumulative Number of Patients with COVID-19 Hospitalized, admitted to the ICU, and Died in UC Health Hospitals, December 13, 2019 to January 6, 2021. Dashed vertical lines correspond to change points in hospitalization that occurred in April 18, May 18, June 25, August 14, September 11, October 15, and November 21, 2020



**Fig. 3** Rate (95% Confidence Intervals) of Patients Who Experienced a Composite Outcome of ICU Admission and/or Death, During Hospitalization for COVID-19 in UC Health Hospitals, 2020

1-year cumulative ICU admission rate for COVID-19 is equitable to previous reports, but the in-hospital mortality rate is smaller than observed in case studies from

earlier in course of the pandemic: ICU admission rates ranged from 14.2% to 35.7% in March–May 2020, where mortality rates ranged from 21.0% to 29.1% over the same



period [2, 9, 11, 21]. Our study captured the experience of patients hospitalized for COVID-19 in five hospitals in California, across which the rates of composite outcome ranged from 18.2% to 34.2%. The variability of this outcome by hospital is likely influenced by differences in patient severity and treatment practices for COVID-19 across hospital settings, which have evolved throughout 2020, and regional fluctuations in the scope of the pandemic.

Differences observed in mortality and severity of COVID-19 among patients that require hospitalization are probably multifactorial. Our sample was drawn from a longer time period, which would include effects from improved treatment options and resource availability that were frequently lacking during earlier stages. Additionally, geographic differences in the distribution of races/ethnicities and the prevalence of chronic conditions that appear to increase the risk of severe illness may contribute to differences in hospital outcomes across the country. Criteria for hospital admission may have changed throughout this pandemic and likely will be driven, at least partially, by the availability of resources and ICU beds, which have fluctuated as well. Despite the documented differences in the outcomes of hospitalized COVID-19 patients, trends in these outcomes across the five hospitals during the study period are consistent, with reasonable fluctuations of the outcomes assessed.

The associations with older age, comorbidities, and race/ethnicity with poor outcomes linked to COVID-19 hospitalization are largely consistent with previous findings. This study also highlighted the increased risk of

poor outcomes in the Asian population of California. In most states and counties, the relatively small proportion of Asian in the population makes awareness of cases and deaths in this community more challenging, as general samples large enough to make conclusions from are difficult to come by. California is one of few states with a sufficiently sizable Asian population for their COVID-19 burden to become unmistakable in the aggregate. There is growing recognition of the burden of COVID-19 among Asian, but data on outcomes among Asian ethnic subgroups remain extremely limited. A recent systematic review and meta-analysis of 50 studies from the US and United Kingdom found higher risk of COVID-19 infection among Asians and Blacks compared to Whites, and possibly an increased risk of ICU admission and death only among Asians compared to Whites [22]. Further studies are needed to investigate the impact of COVID-19 infection and severity in Asian populations, particularly addressing potential differences in Asian ethnic subgroups at a broader geographic scale. These investigations will be critical to appropriately allocate resources to hardest hit communities, including testing and communication regarding seeking care as well as public health policies to mitigate risk factors and improve health equity.

The composite outcome in this study involved an ICU admission and/or in-hospital mortality, which occurred in 27.5% of patients. We reported rates only for patients who were discharged alive or died during the hospitalization by the end of the study period. 61.8% of patients had 1 or more relevant comorbidities and nearly 23% had

5 or more of these pre-existing conditions, which substantially increased the odds of a poor outcome. Using a network-based approach, we found that hypertension, cardiac disease, diabetes, and renal failure are positively and significantly associated to each other in the overall population, a relationship even more evident in patients with a composite outcome.

This study has several limitations. Our findings represent the experience of five hospitals within the UC Health system and therefore may have limited external generalizability to other health care settings, especially outside of California. Since our sample was drawn from electronic medical records and not full chart reviews, our data was also missing reported symptoms and the patients' stated reasons for seeking COVID-19 tests, which could be one or a combination of the presence of COVID-19 symptoms, notification of exposure through contact tracing, or seeking a test in lieu of observing a 14-day quarantine period after travel. Since our analysis was based on ICU admission, death, or discharge over the course of a single hospital stay, no losses to follow-up were represented in our data. Such a large cohort followed over an extended time of period will necessarily include aggregation biases due to differential test availability, hospital admission practices, and documentation across the five medical centers, especially as public health advice evolved over the observation period. This could very well have obscured evolving demographic trends as the pandemic developed, or introduced a confounding bias in crude measures. Finally, this study does not address or account for the possibility of patients dying elsewhere. Cases who were tested at UC Health and sought care outside the system were not captured in this database, meaning any subsequent hospitalizations, ICU admissions, or mortality events of positive, confirmed cases outside the UC Health system would not have been captured either. Notwithstanding these limitations, this study provides comparative epidemiologic characteristics of a diverse and underrepresented population of patients admitted to the hospital with COVID-19 over an entire year of the pandemic. Particularly relevant is the captured experience of Asians hospitalized due to COVID-19, and the differences in demographic characteristics and associations of comorbidities with each other and with poor outcomes.

## Conclusions

In this study, we found that older patients, with multiple comorbidities, identifying as Hispanic/Latino or Asian were more likely to be admitted to the intensive care unit and/or die during hospitalization at five UC Health medical centers. The overall mortality rate observed is significantly lower than what has been documented in hospitalized patients with COVID-19 from

the early stages of the pandemic, despite the reported high levels of comorbidities. These findings provide additional evidence of the impact of COVID-19 in system of hospitals in California. While the comparatively low mortality rate is reassuring, the differential impact on racial/Ethnic minorities requires the implementation of an equitable solution.

## Abbreviations

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19: Coronavirus disease 2019; UC Health: University of California Five Academic Medical Centers; UC Davis: University of California Davis, Medical Center; UCI: University of California Irvine, Medical Center; UCLA: University of California Los Angeles, Medical Center; UCSD: University of California San Diego, Medical Center; UCSF: University of California San Francisco, Medical Center; ICU: Intensive Care Unit; ICU Days: Days spent in the Intensive Care Unit; LOS: Days spent in the hospital before discharge or death; ICD-10-CM: International Classification of Diseases, 10th Revision, Clinical Modification; AIAN: American Indian/Alaskan Native.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12879-021-06640-4>.

**Additional file 1: Table S1.** Severe acute respiratory syndrome coronavirus 2 Lab Tests. **Table S2.** International classification of disease codes for comorbidities. **Appendix S1.** Correlation Network of comorbidities. **Appendix S2.** Change-point detection analysis of hospitalizations, ICU admissions, and In-Hospital deaths. **Figure S1.** Fits of data and change points.

## Acknowledgements

Dr. Nuño wish to thank Dr. James M. Bugni and Blanca Nuño for supporting this research effort and providing critical feedback to improve this study. We additionally wish to thank members of the IT Health Informatics division at UC Davis. Hemanth Tatiparthi and Ranjit Singh created the local CORDS database, Steve Covington provided advice about querying the database, and Brian Paciotti helped evaluate data irregularities among sites.

## Reporting guidelines

This manuscript was prepared according to STROBE guidelines for cohort studies.

## Preprint

A previous draft of this manuscript appears on the MedRxiv preprint service: <https://doi.org/10.1101/2021.01.29.21250788>.

## Authors' contributions

MN had full access to the limited dataset in the study and takes full responsibility for the integrity of the data and accuracy of the analysis. MN and GR conceptualized and designed the study. MN, YG, and DP executed the statistical analyses. All authors were involved in interpretation of the results. MN and AJ drafted the manuscript. All authors read and approved the final manuscript.

## Funding

None reported.

## Availability of data and materials

The data that support the findings of this study are made available by University of California Office of the President and the University of California. Biomedical, Research, Acceleration, Integration, and Development (UC BRAID) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are

however available from the corresponding author upon reasonable request and with permission of the UC BRAID.

## Declarations

### Ethics approval and consent to participate

The University of California COVID Research Data Set (CORDS) was determined exempt from human subject protection under the UC Davis Office of Research IRB Administration protocol 1604619-1. Informed Consent was not deemed necessary for de-identified data by Nicholas and Kent Anderson at the UC Davis Clinical and Translational Science Award (CTSC) Biomedical Informatics Program.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Public Health Sciences, University of California, One Shields Avenue, Medical Sciences 1C, Davis, CA 95616, USA. <sup>2</sup>Department of Surgery, University of California, Davis, USA. <sup>3</sup>UNICAP, ICAM-Tech International School, Universidade Católica de Pernambuco, Recife, Brazil. <sup>4</sup>Centro de Investigación en Matemática Pura y Aplicada (CIMPA), University of Costa Rica, San José, Costa Rica.

Received: 15 March 2021 Accepted: 19 July 2021

Published online: 10 September 2021

## References

- Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). COVID-19 Dashboard. <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>. Published May 25, 2020. Accessed 25 May 2020.
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. *JAMA*. 2020;323(20):2052–2059. <https://doi.org/10.1001/jama.2020.6775>.
- Ko JY, Danielson ML, Town M, Derado G, Greenlund KJ, Kirley PD, Alden NB, Yousey-Hindes K, Anderson EJ, Ryan PA, Kim S, Lynfield R, Torres SM, Barney GR, Bennett NM, Sutton M, Talbot HK, Hill M, Hall AJ, Fry AM, Garg S, Kim L; COVID-NET Surveillance Team. Risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization: COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. *Clin Infect Dis*. 2021;72(11):e695–e703. <https://doi.org/10.1093/cid/ciaa1419>.
- Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. *JAMA Intern Med*. 2020;180(10):1345–55.
- Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US National sample of patients with COVID-19. *JAMA Netw Open*. 2020;3(12):e2029058.
- Izurieta HS, Graham DJ, Jiao Y, et al. Natural history of COVID-19: risk factors for hospitalizations and deaths among >26 million U.S. Medicare beneficiaries. *J Infect Dis*. 2020;223:945.
- Fan Y, Wang X, Jun Z, Mo D, Xiao X. The risk factors for the exacerbation of COVID-19 disease: a case-control study. *J Clin Nurs*. 2020;30:725.
- Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1–30, 2020. *MMWR*. 2020;69(15):458–64.
- Bhargava A, Sharma M, Riederer K, Fukushima EA, Szpunar SM, Saravolatz L. Risk factors for in-hospital mortality from COVID-19 infection among black patients—an urban center experience. *Clin Infect Dis*. 2020. <https://doi.org/10.1093/cid/ciaa1468>.
- Ji D, Zhang D, Xu J, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. *Clin Infect Dis*. 2020;71(6):1393–9.
- Kabarriti R, Brodin NP, Maron MI, et al. Association of race and ethnicity with comorbidities and survival among patients with COVID-19 at an urban medical center in New York. *JAMA Netw Open*. 2020;3(9):e2019795.
- Hamer M, Gale CR, Kivimäki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: a community-based cohort study of adults in the United Kingdom. *Proc Natl Acad Sci U S A*. 2020;117(35):21011–3.
- Sun H, Jain A, Leone MJ, et al. CoVA: an acuity score for outpatient screening that predicts coronavirus disease 2019 prognosis. *J Infect Dis*. 2021;223(1):38–46.
- Bhargava A, Fukushima EA, Levine M, et al. Predictors for severe COVID-19 infection. *Clin Infect Dis*. 2020;71(8):1962–8.
- Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): cases in the US. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>. Published May 25, 2020. Accessed 25 May 2020.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054–62.
- Hidalgo CA, Blumm N, Barabasi AL, Christakis NA. A dynamic network approach for the study of human phenotypes. *PLoS Comput Biol*. 2009;5(4):e1000353.
- Edwards AW, Cavalli-Sforza LL. A method for cluster analysis. *Biometrics*. 1965;21:362–75.
- Scott AJ, Knott M. A cluster analysis method for grouping means in the analysis of variance. *Biometrics*. 1974;30(3):507–12.
- Sen A, Srivastava MS. On tests for detecting change in mean. *Ann Stat*. 1975;3(1):98–108.
- Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. *N Engl J Med*. 2020;382(26):2534–43.
- Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. *EClinicalMedicine*. 2020;29:100630.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

